Evaxion granted 180-day compliance extension by nasdaq as it restores equity above minimum requirement

Copenhagen, denmark, january 28, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, has received notice from the nasdaq stock market llc (“nasdaq”) that it has been granted a 180-day extension to comply with nasdaq's minimum stockholder's equity requirement. meanwhile, evaxion has already restored its equity above the nasdaq minimum requirement.
EVAX Ratings Summary
EVAX Quant Ranking